Elsilimomab
Based on 1 Customer Validation
Elsilimomab (B-E8) is a IgG1 monoclonal antibody against interleukin-6 (IL-6), with a KD of 22 pM and an IC50 of 1.4 nM. Elsilimomab can be used for the research of multiple myeloma, renal cell carcinoma, and rheumatoid arthritis (RA).
For research use only. We do not sell to patients.
- Purity: 98.44%
- CAS No.: 468715-71-1
- Molecular Weight:145.96 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
|
IL-6 1.4 nM (IC50) |
Elsilimomab specifically inhibits IL-6 but not LIF (leukemia inhibitory factor)-induced cell growth[2].
Elsilimomab (20 μg/mL) neutralizes human IL-6[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Murine B9 cells
-
Concentration:20 μg/mL
-
Incubation Time:3 days
-
Result:B9 cells were stimulated with human IL-6, which was effectively neutralized by antibody Elsilimomab.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Immobilized IL-6 Protein, Human can bind Elsilimomab. The EC50 for this effect is 32.74 ng/mL. -
Flow cytometric analysis of 1.5×106 Siha cells labeling Elsilimomab (HY-P99287, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 468715-71-1
-
Appearance Liquid
-
Molecular Weight 145.96 kDa
-
Color Colorless to light yellow
-
SMILES
[Elsilimomab]
-
Synonyms
B-E8; Anti-IL-6 MAB B-E8
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (259 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Lee JJ, et al. A high-affinity protein binder that blocks the IL-6/STAT3 signaling pathway effectively suppresses non-small cell lung cancer. Mol Ther. 2014 Jul;22(7):1254-1265. [Content Brief]
[2]. Burger R, et al. Due to interleukin-6 type cytokine redundancy only glycoprotein 130 receptor blockade efficiently inhibits myeloma growth. Haematologica. 2017 Feb;102(2):381-390. [Content Brief]
[3]. Finch DK, et al. Whole-molecule antibody engineering: generation of a high-affinity anti-IL-6 antibody with extended pharmacokinetics. J Mol Biol. 2011 Aug 26;411(4):791-807. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)